IL29 (Interferon Lambda 1, also known as IFN-λ1) is a cytokine gene encoding a Type III interferon that plays crucial roles in antiviral immunity, immune modulation, and neuroinflammation. Although primarily studied in the context of viral infections and autoimmune diseases, emerging evidence positions IL29 as a significant player in neurodegenerative disease pathogenesis through its effects on [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and neuroinflammatory cascades. [@kotenko2002][@cully2019]
Gene Structure and Protein
The IL29 gene is located on chromosome 19q13.2 within the Type III interferon gene cluster, which includes IL28A (IFN-λ2) and IL28B (IFN-λ3). The gene spans approximately 3.5 kb and consists of 5 exons encoding a 200-amino acid secreted protein. IL29 shares the same receptor complex (IFN-λR1/IL-10Rβ) with other Type III interferons but signals through a distinct pathway compared to Type I interferons (IFN-α/β). [@lazear2019]
IL29 (Interferon Lambda 1, also known as IFN-λ1) is a cytokine gene encoding a Type III interferon that plays crucial roles in antiviral immunity, immune modulation, and neuroinflammation. Although primarily studied in the context of viral infections and autoimmune diseases, emerging evidence positions IL29 as a significant player in neurodegenerative disease pathogenesis through its effects on [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and neuroinflammatory cascades. [@kotenko2002][@cully2019]
Gene Structure and Protein
The IL29 gene is located on chromosome 19q13.2 within the Type III interferon gene cluster, which includes IL28A (IFN-λ2) and IL28B (IFN-λ3). The gene spans approximately 3.5 kb and consists of 5 exons encoding a 200-amino acid secreted protein. IL29 shares the same receptor complex (IFN-λR1/IL-10Rβ) with other Type III interferons but signals through a distinct pathway compared to Type I interferons (IFN-α/β). [@lazear2019]
The IL-29 protein possesses:
An N-terminal signal peptide for secretion
Six alpha-helices connected by flexible loops
Two conserved disulfide bonds essential for stability
Receptor-binding sites that determine tissue-specific responses
Expression Pattern
IL29 expression is induced by viral infection, [toll-like receptor](/proteins/tlr-signaling-pathway) activation, and pro-inflammatory cytokines. Unlike Type I interferons, which are expressed ubiquitously, IFN-λ signaling is largely restricted to epithelial cells and certain immune cells.
Central Nervous System Expression
Cell Types: Expressed by [neurons](/entities/neurons), [microglia](/cell-types/microglia), and [astrocytes](/cell-types/astrocytes) in response to viral infection
Regional Distribution: Highest expression in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and [basal ganglia](/brain-regions/basal-ganglia)
Induction: RequiresPattern Recognition Receptor (PRR) signaling via RIG-I/MDA5 or TLR3
Signaling Pathway
IL29 signals through a heterodimeric receptor complex:
Receptor Complex: IFN-λR1 (IL-28Rα) + IL-10Rβ (shared with IL-10 family)
Gene Activation: ISGF3 translocates to nucleus → binds ISRE elements → transcription of interferon-stimulated genes (ISGs)
Key Interferon-Stimulated Genes
Antiviral: OAS, MX, IFITM, viperin
Immunomodulatory: PD-L1, MHC-I, IL-12 antagonist
Antiproliferative: p21, p27, TRAIL
Role in Neurodegenerative Diseases
Alzheimer's Disease
IL29 exhibits complex and context-dependent roles in Alzheimer's disease pathogenesis:
Microglial Activation: IL-29 promotes M1 pro-inflammatory microglial polarization, increasing expression of TNF-α, IL-1β, and IL-6 in the brain. This polarization contributes to chronic neuroinflammation and drives disease progression. [@xu2019]
Amyloid Pathology: Studies demonstrate that IL-29 enhances amyloid-β production by upregulating β-secretase (BACE1) expression in neurons and glia. IFN-λ signaling in microglia promotes phagocytic activity but may also increase inflammatory cytokine release that damages neurons.
Tau Pathology: IL-29-mediated neuroinflammation accelerates tau hyperphosphorylation through GSK-3β activation. The inflammatory milieu created by chronic IFN-λ exposure promotes tau seeding and propagation.
Neuronal Dysfunction: IFN-λ signaling in neurons induces expression of antiviral genes that may inadvertently target neuronal survival pathways. Chronic exposure leads to synaptic dysfunction and dendritic spine loss. [@zhao2021]
Parkinson's Disease
Dopaminergic Neuron Vulnerability: IL-29 expression is elevated in the substantia nigra of PD patients. This cytokine promotes neuroinflammation that specifically targets dopaminergic neurons in the substantia nigra pars compacta.
α-Synuclein Pathology: IFN-λ signaling enhances α-synuclein aggregation and propagation. Microglial activation by IL-29 creates a permissive environment for Lewy body formation. [@kim2021]
Neuroinflammation: IL-29 amplifies the innate immune response in PD, increasing pro-inflammatory cytokine production and microglial phagocytic activity. However, this comes at the cost of chronic neuroinflammation.
Therapeutic Potential: Interestingly, some studies show that IFN-λ treatment can reduce α-synuclein pathology in experimental models, suggesting a potential biphasic effect depending on timing and context. [@tateishi2020]
Amyotrophic Lateral Sclerosis
Motor Neuron Vulnerability: IL-29 is upregulated in ALS patients and SOD1 transgenic mice. The cytokine promotes inflammatory activation of microglia that attack motor neurons.
Disease Progression: Treatment with IFN-λ exacerbates disease in ALS mouse models, accelerating motor neuron loss and reducing survival. Neutralization of IFN-λ improves outcomes. [@li2019]
Astrocyte Dysfunction: IL-29 modulates astrocyte reactivity in ALS, promoting pro-inflammatory astrocyte phenotypes that fail to support motor neuron survival.
Multiple Sclerosis
Demyelination: IFN-λ is upregulated in MS lesions and promotes oligodendrocyte death. The cytokine inhibits oligodendrocyte precursor cell (OPC) differentiation, impairing remyelination.
Blood-Brain Barrier: IL-29 increases expression of matrix metalloproteinases (MMPs) that degrade the blood-brain barrier, facilitating immune cell infiltration.
Clinical Trials: Recombinant IFN-λ is being explored therapeutically in MS, with Phase 2 trials showing some benefit in reducing relapse rates.
Therapeutic Implications
Targeting IL-29 Signaling
Neutralizing Antibodies: Anti-IL-29 antibodies are being developed for chronic neuroinflammatory conditions